Purdue Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: New York NY United States (1892)
Status: Defunct (2019)

Organization Overview

First Clinical Trial
1996
NCT00315835
First Marketed Drug
1959
phenyl aminosalicylate (pheny-pas-tebamin)
First NDA Approval
1959
phenyl aminosalicylate (pheny-pas-tebamin)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Imbrium Therapeutics | PURDUE | Purdue Frederick | PURDUE FREDERICK | PURDUE GMP | PURDUE PHARMA | Purdue Pharma, Canada | Purdue Pharma LP | PURDUE PHARMA LP | Purdue Pharma L.P., Stamford, CT

Active Ingredients

Marketed Drugs (14)

buprenorphine (2010)

cycloserine (seromycin) (1964 NDA)

hydrocodone (hycodan) (2014)

hydromorphone (diladid) (2004)

levobupivacaine (chirocaine) (1999 NDA)

methylphenidate (ritalin) (2019)

morphine (1987)

nalmefene (revex) (2022)

naloxone (narcan) (2014)

oxycodone (oxycontin) (2010)

phenyl aminosalicylate (pheny-pas-tebamin) (1959 NDA)

sulfaphenazole (sulfabid) (1961 NDA)

tramadol (Ultram) (2008)

zolpidem (ambien) (2011)

Drugs in Phase 4 Trials (6)

hydromorphone (diladid) (2 trials)

lisdexamfetamine (vyvanse) (2 trials)

methoxyflurane (penthrane) (1 trial)

methylphenidate (ritalin) (12 trials)

nalmefene (revex) (1 trial)

naloxone (narcan) (5 trials)

Drugs in Phase 3 Trials (5)

acetaminophen (tylenol) (1 trial)

buprenorphine (27 trials)

hydrocodone (hycodan) (4 trials)

lemborexant (Dayvigo) (10 trials)

oxycodone (oxycontin) (18 trials)

Drugs in Phase 2 Trials (8)

Key: Purdue Pharmaceuticals (7) Acquired (1)

ibuprofen (motrin) (1 trial)

naproxen (naprosyn) (3 trials)

pregabalin (lyrica) (1 trial)

sx600 (1 trial)

v116517 (3 trials)

v117957 (3 trials)

v120083 (1 trial)

vm902a (1 trial)

Drugs in Phase 1 Trials (14)

capsaicin (qutenza) (1 trial)

celecoxib (celebrex) (1 trial)

ethanol (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

famotidine (pepcid) (1 trial)

fluconazole (diflucan) (1 trial)

interferon alfa-n3 (Alferon-N) (1 trial)

ketoconazole (nizoral) (1 trial)

moxifloxacin (avelox) (3 trials)

naltrexone (revia) (1 trial)

norethindrone (1 trial)

suvorexant (belsomra) (1 trial)

zolpidem (ambien) (2 trials)

zopiclone (Zimovane) (1 trial)

Indications

Approved Indications


 

Anesthesia

Bacterial Infections

Pain

Tuberculosis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 1)

Acute Pain (Phase 4)

Agoraphobia (Phase 4)

Alzheimer Disease (Phase 2)

Anxiety Disorders (Phase 4)

Apnea (Phase 1)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Back Pain (Phase 3)

Chronic Pain (Phase 3)

Cognitive Dysfunction (Phase 2)

Communicable Diseases (Phase 1)

Constipation (Phase 3)

Dementia (Phase 2)

Disease (Phase 4)

Emergencies (Phase 4)

HIV Infections (Phase 1)

Hyperkinesis (Phase 4)

Infections (Phase 1)

Liver Diseases (Phase 1)

Low Back Pain (Phase 3)

Neuralgia (Phase 2)

Neuralgia, Postherpetic (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Pain, Postoperative (Phase 4)

Panic Disorder (Phase 4)

Phobia, Social (Phase 4)

Renal Insufficiency (Phase 1)

Sleep Apnea, Obstructive (Phase 1)

Sleep Apnea Syndromes (Phase 1)

Sleep Initiation and Maintenance Disorders (Phase 3)

Spinal Cord Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 82
  • # of Trial APIs: 33